Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 10,102

Document Document Title
WO/2019/200120A1
The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.  
WO/2019/196950A1
The present invention discloses a compound taking xanthone as a core, a preparation method thereof and an application thereof in OLED. The compound contains a xanthone structure, and at least one N exists in a five-membered ring branched...  
WO/2019/197602A1
A compound with the formula I: (I) and salts and solvates thereof, wherein: R" is a group of formula II: (II) where each of n and m are independently selected from 1, 2 and 3.  
WO/2019/197549A1
The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[l,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for th...  
WO/2019/199908A1
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compos...  
WO/2019/196948A1
Disclosed are a compound using an aryl ketone as a core as represented by general formula (1), a preparation method therefor and an application thereof on an OLED. A parent nucleus of the organic compound is an aryl ketone, the parent nu...  
WO/2019/195104A1
The present disclosure relates to compounds of Formula (I) or (II), as compounds capable of emitting delayed fluorescence, and uses of the compounds in organic light-emitting diodes.  
WO/2019/189867A1
The technical problem of the present invention is to provide a bis-iminobiotin compound which has a structure that enables the easy bonding of a bis-iminobiotin moiety to a drug or a fluorescent compound and is useful for the delivery of...  
WO/2019/184955A1
Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.  
WO/2019/191454A1
The present disclosure relates to compounds of Formula (I), (II), or (III) as compounds capable of emitting delayed fluorescence, and uses of the compounds in organic light-emitting diodes.  
WO/2019/186358A1
The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical co...  
WO/2019/189732A1
The present invention pertains to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, said compound inhibiting the binding of an MLL fusion protein, in which a typical fusion partner gene such as AF4 or A...  
WO/2019/186343A1
The invention relates to compounds of the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutica...  
WO/2019/189778A1
A compound with anticancer activity or a pharmaceutically permissible salt thereof is provided. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof is used. (In the formula, L1 andL2 are the same or differ...  
WO/2019/180683A1
The present disclosure provides novel compounds of Formula (I) below. Compounds of the disclosure act as STING modulators/agonists. The present disclosure further relates to methods of synthesis of compounds of Formula (I) and methods of...  
WO/2019/181645A1
Provided is a compound having an acceptor unit, and a donor unit that has a specific structure. Another purpose of the present invention is to provide a precursor to said compound. Another purpose of the present invention is to provide a...  
WO/2019/183364A1
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further ...  
WO/2019/182960A1
Compounds of Formula (1) as inhibitors of protein tyrosine phosphatase SHP2 are disclosed. The pharmaceutical compositions comprising compounds of Formula 1, methods of synthesis of these compounds, methods of treatment for diseases asso...  
WO/2019/175046A1
The present invention relates to novel condensed bicyclic heterocyclic derivatives of formula (I), wherein B1, B2, B3, B4, R1, R4, R5, R6 and n have the above-mentioned meanings, to agrochemical formulations containing the compounds acco...  
WO/2019/174634A1
A pharmaceutical intermediate compound 3, a preparation method therefor, and use of the compound 3 in the preparation of other compounds.  
WO/2019/174598A1
Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.  
WO/2019/178129A1
The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.  
WO/2019/175045A1
The present invention relates to novel condensed bicyclic heterocyclic derivatives of formula (I), wherein B1, B2, B3, B4, R1, R4, R5, R6 and n have the above-mentioned meanings, to agrochemical formulations containing the compounds acco...  
WO/2019/175607A1
The complex chemistry underlying the extensive transformations involved in terpene indole alkaloid synthesis makes identification of the biosynthetic genes challenging. The present invention relates to methods for producing a terpene ind...  
WO/2019/178368A1
The disclosure is directed to compounds of Formula I, which are inhibitors of protein methyltransferase 5 (PRMT5). Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also d...  
WO/2019/170729A1
The present application relates to an amine compound according to formula (I), (II) or (III) which is suitable for use in electronic devices.  
WO/2019/170691A1
The present application relates to an amine compound of formula (I) which is suitable for use in electronic devices.  
WO/2019/170063A1
The present invention provides a class of indolizine compounds represented by formula (I), pharmaceutically acceptable salts thereof, a preparation method thereof, and a use thereof. The indolizine compounds have an inhibitory effect on ...  
WO/2019/170055A1
The present invention relates to compounds having CDK4/6 kinase inhibitory activity, a pharmaceutical composition thereof and a use thereof. The present invention relates in particular to compounds represented by formula I, and further r...  
WO/2019/170572A1
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.  
WO/2019/166475A1
The present invention relates to synthetic receptors for ionophoric compounds, such as ionophoric toxins. Hence, the invention provides synthetic molecules capable of binding different ionophoric compounds, thereby being suitable for use...  
WO/2019/168847A1
This application relates to compounds of Formula (I) or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatme...  
WO/2019/162524A1
The invention relates to chemical compounds that can be used in particular as structural mimetics of proline-rich peptides. The compounds of the invention are capable of selectively inhibiting ena/VASP-EVH1-mediated protein-protein inter...  
WO/2019/086141A8
The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV rep...  
WO/2019/158107A1
Disclosed in the present invention are a heterocyclic compound, an application thereof and a pharmaceutical composition comprising the same. Provided by the present invention are a heterocyclic compound represented by formula I or a phar...  
WO/2019/158019A1
Disclosed in the present invention are a pyrimidine-fused cyclic compound or a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer, solvate or isotope labeled compound thereof. Also provided in the present invention are a pr...  
WO/2019/160882A1
Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.  
WO/2019/153080A1
The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodru...  
WO/2019/149657A1
The present invention relates to compounds of general formula (I), wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modula...  
WO/2019/149658A1
The present invention relates to compounds of general formula I, wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate...  
WO/2019/151274A1
The present invention provides a compound which has a PDHK-inhibiting activity and is useful for the treatment or prevention of diabetes (type 1 diabetes, type 2 diabetes, etc.), insulin resistance syndrome, metabolic syndrome, hyperglyc...  
WO/2019/151269A1
Provided is a compound that exhibits the effect of reducing the amount of glucosyl ceramide (e.g., the effect of accelerating glucosyl-ceramide metabolism, the effect of inhibiting glucosyl-ceramide synthesis, the effect of accelerating ...  
WO/2019/149205A1
The present invention relates to a benzoheteroaryl derivative and a preparation method and medical application thereof. In particular, the present invention relates to a novel benzoheteroaryl derivative represented by general formula (I)...  
WO/2019/147782A1
The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or in...  
WO/2019/144074A1
Provided herein are rigid macrocycles comprising a poly(peri-naphthalene) diimide (PPNDI) subunit and a second diimide subunit having both high photoluminescent and electron accumulation activities. Also provided herein are methods of pr...  
WO/2019/142555A1
The present invention provides a luminescent film containing at least a phosphorescent compound and a fluorescent compound, wherein the convolution integral value J of the emission spectrum of the phosphorescent compound and the absorpti...  
WO/2019/137430A1
The present invention provides an organic compound of a specific structure. The organic compound is characterized by being represented by the following general formula (1): In the formula (1), X1-X8 are respectively and independently sel...  
WO/2019/138227A1
Compounds that are useful as inhibitors of the activity of Wee-1 kinase are provided. Also provided are pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods...  
WO/2019/136159A1
Provided herein are compositions and methods useful for the expansion of hematopoietic stem and progenitor cells. In accordance with the composition and methods described herein, hematopoietic stem and progenitor cells may be expanded, f...  
WO/2019/134985A1
The invention provides new heterocyclic compounds having the general formula (le), wherein R1, R1a and R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the co...  

Matches 1 - 50 out of 10,102